 |
|
|
| |
Implementation of Long-acting Injectable Cabotegravir-Rilpivirine
for HIV-1 treatment at a Ryan White-funded Clinic in the U.S. South
|
| |
| |
Lauren F. Collins, MD1,2; Della Corbin-Johnson, RPH2; Meron Asrat, MPH2; Tonya Rankins, CPhT2; Latoya Harrison, RPhT2;
Alton Condra, RPH2; Jeri Sumitani, PA-C2; Bradley L. Smith, PharmD2; Wendy S. Armstrong, MD1,2; Jonathan A. Colasanti, MD, MSPH1,2
1Divison of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia; 2Grady Healthcare System, Infectious Diseases Program, Atlanta, Georgia
*Of the 42 referrals, payor source distribution was: 26% Private, 19% Medicare, 10% Medicaid, 45% AIDS Drug Assistance Program (ADAP); however, drug access to date has only been successfully pursued for patients with commercial coverage as opposed to those with federally-funded coverage, i.e., Georgia Medicaid and ADAP, despite attempts to leverage ViiV patient assistance programs.
|
| |
|
|
|
|
|
